Want to see CRBU full AI Analyst Report?
CRBU Stock Chart & Stats
$1.65
$0.05(3.50%)
At close: 4:00 PM EDT
$1.65
$0.05(3.50%)
Day’s Range― - ―
52-Week Range$1.38 - $3.54
Previous CloseN/A
Volume203.30K
Average Volume (3M)1.03M
Market Cap
$168.32M
Enterprise Value$92.08
Total Cash (Recent Filing)$112.31M
Total Debt (Recent Filing)$26.66M
Price to Earnings (P/E)―
Beta2.49
Next Earnings
Mar 11, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding107,207,510
10 Day Avg. Volume959,858
30 Day Avg. Volume1,034,967
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.22
Price to Sales (P/S)13.31
P/FCF Ratio-1.32
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.50Price Target Upside415.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.19
Revenue Forecast (FY)$25.65M
Bulls Say, Bears Say
Bulls Say
Strong Clinical Response DataHigh response and complete response rates provide meaningful clinical validation for vispa-cel. If sustained in larger studies, these results could support differentiation in lymphoma and improve the probability of future commercial adoption.
Off-the-shelf Cell Therapy PlatformAn allogeneic, off-the-shelf model may reduce the manufacturing complexity and waiting time associated with autologous therapies. Advancing toward a pivotal trial creates a defined development path for validating the platform’s scalability.
Manageable LeverageRelatively modest leverage limits debt-service pressure and preserves more flexibility than a highly indebted balance sheet. This provides some capacity to fund clinical development, although continued losses still constrain overall financial resilience.
Bears Say
Persistent Unprofitable OperationsThe company has no commercial product revenue base sufficient to absorb its operating costs, leaving profitability dependent on successful development and partnerships. Continued revenue weakness and large losses raise the risk of further equity dilution.
Substantial Cash BurnOngoing negative cash generation means Caribou must rely on cash reserves, collaborations, or capital markets to advance trials. If development spending remains elevated while revenue stays limited, funding needs could constrain strategy and shareholder returns.
Clinical Safety And Execution RiskSerious adverse events and reported deaths could complicate regulatory review, trial design, enrollment, or adoption even alongside strong efficacy. These risks may require additional monitoring and mitigation, potentially increasing development costs and timelines.
Caribou Biosciences News
CRBU FAQ
What was Caribou Biosciences’s price range in the past 12 months?
Caribou Biosciences lowest stock price was $1.38 and its highest was $3.54 in the past 12 months.
What is Caribou Biosciences’s market cap?
Caribou Biosciences’s market cap is $168.32M.
When is Caribou Biosciences’s upcoming earnings report date?
Caribou Biosciences’s upcoming earnings report date is Mar 11, 2027 which is in 186 days.
How were Caribou Biosciences’s earnings last quarter?
Caribou Biosciences released its earnings results on Aug 13, 2026. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.324 by $0.084.
Is Caribou Biosciences overvalued?
According to Wall Street analysts Caribou Biosciences’s price is currently Undervalued.
Does Caribou Biosciences pay dividends?
Caribou Biosciences does not currently pay dividends.
What is Caribou Biosciences’s EPS estimate?
Caribou Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Caribou Biosciences have?
Caribou Biosciences has 107,207,510 shares outstanding.
What happened to Caribou Biosciences’s price movement after its last earnings report?
Caribou Biosciences reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.324. Following the earnings report the stock price went down -1.863%.
Which hedge fund is a major shareholder of Caribou Biosciences?
Currently, no hedge funds are holding shares in CRBU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Caribou Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.50 (415.15% Upside)
$8.50 (415.15% Upside)
Blogger Sentiment
Bullish
CRBU Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 117.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.13%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-35.37%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Caribou Biosciences
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
CRBU Stock 12 Month Forecast
Average Price Target
$8.50
▲(415.15% Upside)
Technical Analysis
Ownership Overview
4.31% Insiders
5.38% Mutual Funds
10.07% Other Institutional Investors
68.33% Public Companies and
Individual Investors